Company research
SELLAS Life Sciences Group, Inc.
CIK 1390478Updated Sep 24, 2026
SecuritySLS · NASDAQ · equity
Name history
GALENA BIOPHARMA, INC. · through Dec 15, 2017Galena Biopharma, Inc. · through Dec 15, 2017RXI PHARMACEUTICALS CORP · through Sep 21, 2011
SLS price & chart
Loading TradingView…
NASDAQ:SLS on TradingView ↗About the company
Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
SCHEDULE 13G filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
4 filing
S-8 filing
Other Events
Items 8.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 78,345,000Source | 19,432,000Source | 6,219,000Source | 20,943,000Source |
| GoodwillUSD | 1,914,000Source | 1,914,000Source | 1,914,000Source | 1,914,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 71,793,000Source | 13,886,000Source | 2,530,000Source | 17,125,000Source |
| Assets, CurrentUSD | 75,211,000Source | 16,327,000Source | 3,172,000Source | 17,756,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,318,000Source | 2,341,000Source | 542,000Source | 531,000Source |
| Operating Lease, Right-of-Use AssetUSD | 963,000Source | 925,000Source | 858,000Source | 874,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 7,474,000Source | 9,967,000Source | 14,195,000Source | 16,092,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 15,000Source | 7,000Source | 3,000Source | 2,000Source |
| Retained Earnings (Accumulated Deficit)USD | -274,988,000Source | -248,125,000Source | -217,244,000Source | -179,904,000Source |
| Stockholders' Equity Attributable to ParentUSD | 70,871,000Source | 9,465,000Source | -7,976,000Source | 4,851,000Source |
| Additional Paid in Capital, Common StockUSD | 345,844,000Source | 257,583,000Source | 209,265,000Source | 184,753,000Source |
| Liabilities and EquityUSD | 78,345,000Source | 19,432,000Source | 6,219,000Source | 20,943,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 7,017,000Source | 9,510,000Source | 13,735,000Source | 15,515,000Source |
| Operating Lease, Liability, CurrentUSD | 544,000Source | 544,000Source | 446,000Source | 372,000Source |
| Accounts Payable, CurrentUSD | 2,948,000Source | 3,500,000Source | 5,639,000Source | 3,357,000Source |
| Operating Lease, Liability, NoncurrentUSD | 457,000Source | 457,000Source | 460,000Source | 573,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 3,525,000Source | 5,466,000Source | 7,650,000Source | 6,286,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,956,000Source | 1,564,000Source | 2,094,000Source | 1,726,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -535,000Source | -2,139,000Source | 2,301,000Source | 1,213,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -28,389,000Source | -35,402,000Source | -31,410,000Source | -23,809,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 0Source | -5,500,000Source | -4,500,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 527,000Source | 64,000Source | 31,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 86,296,000Source | 46,758,000Source | 22,315,000Source | 24,079,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 57,907,000Source | 11,356,000Source | -14,595,000Source | -4,230,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 71,893,000Source | 13,986,000Source | 2,630,000Source | 17,225,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,956,000Source | 1,564,000Source | 2,094,000Source | 1,726,000Source |
| GoodwillUSD | 1,914,000Source | 1,914,000Source | 1,914,000Source | 1,914,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -26,863,000Source | -30,881,000Source | -37,340,000Source | -41,301,000Source |
| Nonoperating Income (Expense)USD | 1,411,000Source | 632,000Source | 529,000Source | 649,000Source |
| Operating Lease, ExpenseUSD | 600,000Source | 600,000Source | 500,000Source | 500,000Source |
| Proceeds from Issuance of Common StockUSD | — | 0Source | 289,000Source | 1,048,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 1,000,000Source |
| Cost of RevenueUSD | 0Source | 0Source | 0Source | 100,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 12,252,000Source | 12,417,000Source | 13,862,000Source | 12,582,000Source |
| Operating Income (Loss)USD | -28,274,000Source | -31,513,000Source | -37,869,000Source | -41,950,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -26,863,000Source | -30,881,000Source | -37,340,000Source | -41,301,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -26,863,000Source | -30,881,000Source | -37,340,000Source | -41,301,000Source |
| Earnings Per Share, BasicUSD per share | -0.25Source | -0.5Source | -1.34Source | -2.13Source |
| Earnings Per Share, DilutedUSD per share | -0.25Source | -0.5Source | -1.34Source | -2.13Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 109,051,215Source | 61,202,412Source | 27,777,111Source | 19,395,709Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 109,051,215Source | 61,202,412Source | 27,777,111Source | 19,395,709Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 28,274,000Source | 31,513,000Source | 37,869,000Source | 42,950,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -9,569,000Source | -9,535,000Source | -10,116,000Source | -17,825,000Source |
| Interest Income (Expense), NetUSD | — | — | 525,000Source | 317,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 1,411,000Source | 632,000Source | — | — |
| Nonoperating Income (Expense)USD | 1,411,000Source | 632,000Source | 529,000Source | 649,000Source |
| Operating Lease, ExpenseUSD | 600,000Source | 600,000Source | 500,000Source | 500,000Source |
Filing attachments
tm2529505d1_ex4-1.htm · 8-K · 2025-10-27
EX-4.1 2 tm2529505d1_ex4-1.htm EXHIBIT 4.1 EXHIBIT 4.1 WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Issuance Date: _______, 2025 Initial Exercise Date: _______, 2025 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se…
Read attachment ↗tm2529505d1_ex99-1.htm · 8-K · 2025-10-27
EX-99.1 5 tm2529505d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise…
Read attachment ↗tm2525854d1_ex4-1.htm · 8-K · 2025-09-11
EX-4.1 2 tm2525854d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT…
Read attachment ↗tm2525854d1_ex99-1.htm · 8-K · 2025-09-11
EX-99.1 4 tm2525854d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds NEW YORK, Sep. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exerci…
Read attachment ↗tm254790d1_ex4-1.htm · 8-K · 2025-01-29
EX-4.1 3 tm254790d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: _______, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft…
Read attachment ↗tm254790d1_ex4-2.htm · 8-K · 2025-01-29
EX-4.2 4 tm254790d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: _______, 2025 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “ Warrant ”) certifies that, for value received, _____________ or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof…
Read attachment ↗